Direct payment by patients for treatment with drugs still in development is the subject of controversy. The matter goes deeper than it might first appear.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oldham, R. Who's paying for new drugs?. Nature 332, 795 (1988). https://doi.org/10.1038/332795a0
Issue Date:
DOI: https://doi.org/10.1038/332795a0